Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 3/20 | 0.42 |
| ▸ | EPHX1 | P07099 | 2/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.39 |
| ▸ | NAAA | Q02083 | 1/20 | 0.39 |
| ▸ | CES2 | O00748 | 1/20 | 0.38 |
| ▸ | CES1 | P23141 | 1/20 | 0.38 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.38 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.38 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.38 |
| ▸ | PRMT3 | O60678 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL923552 | 0.82 | EPHX1 (0.54) | EPHX2EPHX1SMN1; SMN2HSD17B10HDAC6 | |
| SCHEMBL23384656 | 0.81 | ALDH1A1 (0.34) | EPHX2EPHX1HSD17B10KMT2A | |
| SCHEMBL23366831 | 0.80 | EPHX1 (0.51) | EPHX1SMN1; SMN2HSD17B10HDAC6KMT2A | |
| SCHEMBL21232394 | 0.80 | EPHX1 (0.42) | EPHX2EPHX1SMN1; SMN2HSD17B10NAAA | |
| SCHEMBL8231996 | 0.78 | EPHX1 (0.61) | EPHX1SMN1; SMN2HSD17B10NAAANPSR1 | |
| SCHEMBL784986 | 0.78 | CYP2D6 (0.44) | EPHX2EPHX1SMN1; SMN2HSD17B10NAAA | |
| SCHEMBL29618895 | 0.77 | BTK (0.50) | EPHX1SMN1; SMN2HSD17B10KMT2A | |
| SCHEMBL24337161 | 0.75 | CES2 (0.44) | EPHX2EPHX1SMN1; SMN2HSD17B10NAAA | |
| SCHEMBL23354173 | 0.75 | CYP2D6 (0.41) | EPHX2EPHX1SMN1; SMN2HSD17B10NAAA | |
| SCHEMBL14932795 | 0.75 | CES2 (0.44) | EPHX2EPHX1SMN1; SMN2HSD17B10NAAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1650185-B1 | PROCESS FOR PRODUCTION OF OPTICALLY ACTIVE BETA-HYDROXY- ALPHA-AMINOCARBOXYLIC ACID DERIVATIVES | NISSAN CHEMICAL IND LTD (JP) | 2013-05-01 | — | — | EP | disclosed |
| US-7799941-B2 | Process for producing optically active β-hydroxy-α-aminocarboxylic acid derivative | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2010-09-21 | — | — | US | disclosed |
| US-20060167300-A1 | Process for producing optically active ss-hydroxy alpha aminocarboxylic acid derivative | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2006-07-27 | — | — | US | disclosed |
| EP-1650185-A1 | PROCESS FOR PRODUCTION OF OPTICALLY ACTIVE BETA-HYDROXY- ALPHA-AMINOCARBOXYLIC ACID DERIVATIVES | Nissan Chemical Industries, Ltd. (JP) | 2006-04-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060167300-A1 | Process for producing optically active ss-hydroxy alpha aminocarboxylic acid derivative | ALDH7A1, HCAR1, ALAD | EPHX2 308/4885EPHX1 494/4885SMN1; SMN2 3508/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.